Josh Johnson

Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis.

M. Mingueneau, J. Lyssikatos, T. Bohnert, 2021, Journal of medicinal chemistry.

Fragile X Associated Primary Ovarian Insufficiency (FXPOI): Case Report and Literature Review

R. Pyeritz, L. Nelson, Y. Cohen, 2018, Front. Genet..